NMS · Biotechnology

PLRX (PLRX) Stock

$1.10 +1.39% NMS: PLRX Healthcare

Valuation

MetricValue
Price$1.10
Market Cap$67.80M
P/E Ratio-0.49
P/B Ratio0.41
P/S Ratio0.00
EPS (TTM)$-2.43
52-Week High$1.95
52-Week Low$1.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-82.32%
ROA-66.22%
ROCE-82.87%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.17
Current Ratio12.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$8.0M$10.0M$2.0M$0$0
Operating Profit$-98.0M$-127.0M$-184.0M$-228.0M$-150.0M
Net Profit$-97.0M$-123.0M$-161.0M$-210.0M$-149.0M
EPS$-2.71$-2.94$-2.75$-3.47$-2.43
Op Margin-1288.1%-1313.4%-11654.8%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$221.0M$351.0M$512.0M$397.0M$225.0M
Total Liabilities$22.0M$37.0M$39.0M$93.0M$44.0M
Cash$52.0M$34.0M$63.0M$71.0M$45.0M
Borrowings$7.0M$16.0M$11.0M$60.0M$29.0M

Latest News

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors GlobeNewswire · Jul 13, 2026 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results GlobeNewswire · May 11, 2026 Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference GlobeNewswire · May 6, 2026 Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors GlobeNewswire · Apr 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-75.0M$-95.0M$-116.0M$-156.0M$-128.0M
Investing Cash Flow$72.0M$-152.0M$-128.0M$136.0M$134.0M
Financing Cash Flow$0$1.0M$5.0M$0$0
Net Cash Flow$1.0M$-18.0M$31.0M$8.0M$-26.0M
Free Cash Flow$-77.0M$-96.0M$-117.0M$-159.0M$-129.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-132.98%
Quick Ratio16.89
Interest Coverage-50.00
Return 1Y-20.14%
Return 3Y-93.93%
Return 5Y-95.52%

Ownership

Insiders Held2.23%
Institutions Held82.05%
Institutions Float Held83.92%
Institutional HolderSharesReport Date
Tang Capital Management, LLC6,143,1322026-03-31
Citadel Advisors Llc3,226,5992026-03-31
Blue Owl Capital Holdings LP2,969,1992026-03-31
Adar1 Capital Management, LLC 2,585,1262026-03-31
Acadian Asset Management. LLC2,416,5082026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADVMAdverum Biotechnologies, Inc. $4.36 +0.00% -0.66 $96.26M 0.00%
ARTV $11.27 -2.68% -2.29 $278.56M 0.00%
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
COYA $4.00 -6.21% -2.62 $72.84M 0.00%
GUTS $0.80 +3.62% -0.40 $57.83M 0.00%

About PLRX

PLRX is led by CEO Bernard Coulie, employs 171 people, headquartered in US, publicly traded since 2020.

PLRX stock trades at $1.10 with a market capitalization of $67.80M. The stock is valued at a price-to-earnings (P/E) ratio of -0.49, price-to-book of 0.41, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.06 and $1.95, and currently trades 43.6% below its 52-week high.

On profitability, PLRX generates a return on equity (ROE) of -82.32%, return on capital employed of -82.87%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides